Handelsbanken Fonder’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Handelsbanken Fonder’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-84,000	Closed	-$311K	–	212
2017 Q4	$311K	Hold	84,000	–	–	0.01%	184
2017 Q3	$344K	Hold	84,000	–	–	0.01%	187
2017 Q2	$312K	Hold	84,000	–	–	0.01%	169
2017 Q1	$348K	Hold	84,000	–	–	0.01%	168
2016 Q4	$362K	Buy	+84,000	New	+$543K	0.01%	155

Handelsbanken Fonder's CASC Position: Q1 2018 in Review

Handelsbanken Fonder sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 84,000 shares — an estimated $311K sold.

Handelsbanken Fonder first reported a position in CASC in Q4 2016 and held it in 5 quarters. The position peaked at $362K in Q4 2016. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Handelsbanken Fonder reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Handelsbanken Fonder sold 84,000 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $311K.
Handelsbanken Fonder first reported a position in Cascadian Therapeutics, Inc. in Q4 2016 and held it in 5 quarters.
Handelsbanken Fonder's Cascadian Therapeutics, Inc. position peaked at $362K in Q4 2016.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Handelsbanken Fonder's 13F filing for Q1 2018, filed 18 May 2018.